Please assess the completion status of the following clinical trial:

Trial Title: Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~A subject was eligible for inclusion in this study if all of the following criteria applied:~1. Male or non-pregnant, non-breastfeeding female subjects with a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical conditions expected to require daily NSAID therapy for at least 6 months, who were~   * 18-49 years of age and had a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years OR, who were~  * 50 years of age and older (These subjects did not require a history of a documented, uncomplicated gastric or duodenal ulcer within the past 5 years.)~2. Female subjects were eligible for participation in the study if they were of~   * non-childbearing potential (i.e., physiologically incapable of becoming pregnant);~  * childbearing potential, had a negative pregnancy test at Screening, and at least 1 of the following applied or was agreed to by the subject:~  * Female sterilization or sterilization of male partner~  * Hormonal contraception by oral route, implant, injectable, vaginal ring~  * Any intrauterine device with published data showing that the lowest expected failure rate is \< 1% per year~  * Double barrier method (2 physical barriers or 1 physical barrier plus spermicide)~  * Any other method with published data showing that the lowest expected failure rate is \< 1% per year~3. Each subject was required to understand and comply with study procedures required of a subject and was able and willing to provide written informed consent prior to any study procedures being performed.~Exclusion Criteria~A subject was not eligible for this study if any 1 or more of the following criteria applied:~1. History of hypersensitivity to esomeprazole or to another PPI~2. History of allergic reaction or intolerance to any NSAID (including aspirin) and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps~3. Participation in any study of an investigational treatment in the 4 weeks before Screening~4. Presence of uncontrolled acute or chronic medical illness, e.g., GI disorder, hypertension, diabetes, thyroid disorder, depression and/or infection that would have endangered a subject if they were to have participated in the study~5. GI disorder or surgery leading to impaired drug absorption~6. Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the investigator's opinion would have endangered a subject if they were to have participated in the study~7. Schizophrenia or bipolar disorder~8. Use of any excluded concomitant medication (see Section 9.4.8)~9. A recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including overuse/abuse of narcotics for management of pain~10. Serious blood coagulation disorder, including use of systemic anticoagulants~11. Positive test result for H. pylori at Screening~12. Screening endoscopy showing any gastric or duodenal ulcer at least 3 mm in diameter with depth~13. Screening laboratory alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \> 2 times the upper limit of normal~14. Estimated creatinine clearance \< 30 ml/min~15. Other than noted specifically, any screening laboratory value that was clinically significant in the investigator's opinion and would have endangered a subject if they were to have participated in the study~16. History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PN400 (Type: EXPERIMENTAL): Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
- Naproxen (Type: ACTIVE_COMPARATOR): Naproxen 500 mg dosed twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).